PYC Therapeutics

Australia
Nedlands, Western Australia, Australia, 6009

Company profile

PYC Therapeutics company profile

PYC Therapeutics is a clinical-stage biotechnology company specializing in RNA-based therapies targeting genetic diseases. It leverages a proprietary delivery system using cell‑penetrating peptides (CPPs) conjugated to phosphorodiamidate morpholino oligomers (PMOs) to enhance cellular uptake. The company’s pipeline focuses on inherited conditions affecting the eye, central nervous system, and kidney, including ongoing Phase 1 and natural history studies.

Business identity

Contact email
[email protected]
Phone number
+61 8 6151 0992
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$50,000+
Founded
2005-01-01, Year

Headquarters

Postal code
6009
Country code
AU
Continent
Oceania

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
1
Total equity funding
$26.3M
Last funding
Post IPO Equity / $26.3M / 2024-03-14
Last equity funding
Post IPO Equity / $26.3M
Articles
10
Exited on
2005-03-30

Founders and investors

No public relation records are available.